Many clinically effective therapeutic agents can exhibit localized and systemic effects that are manifestly different from their intended primary pharmacological mode of action. Macrolide antibiotics such as erythromycin and its derivatives are no exception. In addition to their antibacterial action, this class of antibiotics exhibits anti-inflammatory activity in a variety of airway diseases such as asthma and diffuse panbronchiolitis that is separate and distinct from a direct antibacterial action. A variety of erythromycin derivatives have been shown to be clinically beneficial in these airway diseases. The anti-inflammatory activities of these macrolide antibiotics are becoming a research topic of intense interest. Recent work in this field has led to the understanding of the various physiological, cellular and molecular processes of the inflammatory response that are inhibited or suppressed by these compounds. This review presents a brief summary of the fascinating recent work in this active research area. ß 2001 Published by Elsevier Science B.V. on behalf of the Federation of European Microbiological Societies.
Introduction
This brief review covers recent ¢ndings in the research conducted on the use of macrolide antibiotics in the treatment of pulmonary in£ammation. Most chronic airway disorders are the result of a lung injury that results in the in¢ltration of in£ammatory cells such as neutrophils, macrophages, lymphocytes, eosinophils, or mast cells. The nature of the injury (e.g. infectious, smoke inhalation or allergy) will determine the pattern of cell in¢ltration, as will the time elapsed since the onset of the injury [1] . The in¢ltration of these in£ammatory cells depends on the local generation of soluble chemotactic factors such as cytokines, complement fragments, or lipid products, which attract in£ammatory cells into the lung.
Macrolide or polyketide antibacterial compounds are a multitude of polyoxygenated fungal and bacterial secondary metabolites which are assembled from C 3 units [2] . That is, propionyl-S-CoA is used as a starter piece and successive additions of methylmalonyl-S-CoA are used to elongate the growing macrolide chain. Most of these metabolites possess large ring structures, hence the name macrocyclic or macrolide.
The macrolide family of antibiotic therapeutic agents is capable of more than one pharmacological mode of action. They exhibit separate and distinct antibacterial and anti-in£ammatory actions. Macrolide antibiotics, which have been known to reduce in£ammation associated with a variety of airway diseases since the early 1970s [3] , include erythromycin, azithromycin, clarithromycin and roxithromycin, as well as many other compounds (Fig. 1) . They are well known antibacterial agents and are widely used in the chemotherapeutic treatment of a variety of infectious diseases. The broad spectrum antibacterial activity as well as good tissue penetration have led to the widespread use of these macrolide antibiotics for many years.
In addition to their antibacterial e¡ects, increasing evidence suggests that macrolides may play a role in the modulation of the immune responses in a variety of airway diseases. E¡ective modulation of the in£ammatory response by macrolide antibiotics has been shown in airway diseases such as asthma [4, 5] , di¡use panbronchiolitis [6, 7] and in a variety of bacterial and viral airway infections caused by Streptococcus pneumoniae [8] , Pseudomo-nas aeruginosa [9] , Haemophilus in£uenzae [10] , and in£u-enza virus [11] .
The anti-in£ammatory e¡ects of macrolides in£uence a wide, diverse series of cellular events [12] and exert their anti-in£ammatory e¡ects at a variety of di¡erent sites. The interaction between macrolides, epithelial cells and leukocytes may play an important regulatory role in in£amma-tion. Macrolides can accumulate in leukocytes, reaching concentrations that are signi¢cantly higher than therapeutic concentrations in serum [13] . This might contribute to their anti-in£ammatory e¡ects and account for alteration of other cellular functions in leukocytes. Consistent with their accumulation in leukocytes, e¡ects on leukocyte synthesis of several cytokines, oxidant molecules such as hydrogen peroxide, nitric oxide and superoxide, adhesion molecules as well as degranulation of phagolysosomes and chemotaxis have been reported suggesting an intracellular target(s) for macrolide anti-in£ammatory action [14^16] .
Several di¡erent macrolides have been evaluated for differing abilities to mediate a variety of in£ammation processes. Di¡erences in anti-in£ammatory activity have been reported between di¡erent macrolides [13, 17] . The number of atoms in the macrolide ring system may be a signi¢cant factor in the anti-in£ammatory activity of a given macrolide. Macrolides having 14-and, to a lesser extent, 15-member rings display substantial anti-in£ammatory activity [18] . However, the anti-in£ammatory e¡ect of the macrolide antibiotics with 16-member rings such as josamycin [14, 19] and spiramycin [20^22] is highly variable and controversial.
Macrolides and pulmonary in£ammation
Clinical studies have documented the e¤cacy of macrolide therapy in the reduction of airway hyperresponsiveness that is observed in asthma and other pulmonary disorders [4] . However, the mechanism(s) of action are not well understood.
Konno et al. [23] demonstrated that pretreatment of mitogen-activated human peripheral blood leukocytes with roxithromycin suppressed interleukins (IL) 2^4 and tumor necrosis factor K (TNF-K) secretion. Additional work demonstrated that roxithromycin reduced bronchial responsiveness to methacholine after cytokine induction by intratracheal injection of lipopolysaccharide (LPS). Furthermore, a single 5 mg kg 31 daily dose of this macrolide signi¢cantly inhibited the appearance of IL-3, IL-4, IL-5 and TNF-K. Clarithromycin has been shown to suppress bronchial hyperresponsiveness associated with eosinophilic in£ammation in asthma patients [24] . Eosinophil and eosinophilic cationic protein levels were signi¢cantly decreased in blood and sputum samples after macrolide treatment.
The airway disease di¡use panbronchiolitis is characterized by severe chronic in£ammation localized in the respiratory bronchioles [6] . Although the pathophysiology is unknown, P. aeruginosa pulmonary infection likely plays a role [6] . Before the advent of erythromycin therapy, the survival rate of patients was 12.4^21.9% but after erythromycin survival it is greater than 90% despite erythromycin having neither bacteriostatic nor bacteriocidal activity against Pseudomonas sp. [6, 25] . This suggests that macrolides likely exert their e¡ect by reducing in£ammation rather than by an antimicrobial e¡ect. Consistent with this concept, erythromycin suppresses Pseudomonad-induced IL-8 production, and in addition, erythromycintreated patients with di¡use panbronchiolitis exhibit decreased levels of IL-1L and TNF-K [6] . Increased percentages of CD8+, CD4+ and CD3+ lymphocytes were found in peripheral blood from patients with di¡use panbronchiolitis and treatment with erythromycin resulted in a decrease in these percentages [6] .
Other than panbronchiolitis, macrolides are not commonly used as anti-in£ammatory agents in airway disorders. Although there is evidence that macrolides are e¡ec-tive in asthma [3, 4] , the drugs are not commonly used for their anti-in£ammatory e¡ect and the NIH asthma guidelines do not recommend macrolides as anti-in£ammatory agents [26] . For other lung disorders the evidence of clinical improvement is either unknown or weak. Nevertheless, several in vitro studies have suggested the potential for bene¢cial actions in in£ammatory airway disorders. However, a 10-patient pilot study with clarithromycin showed no e¡ect on forced expiratory volume in 1 s and no signi¢cant e¡ect on airway indices of in£ammation in cystic ¢brosis such as neutrophils or IL-8. Larger trials in cystic ¢brosis and asthma are currently ongoing and may provide more de¢nitive answers to the clinical utility of macrolides in these disorders.
Macrolide structure and in£ammation
The chemical structures of several macrolides have been examined with respect to their anti-in£ammatory properties. Erythromycin A derivatives that contain a 14-or 15-member ring structure, including clarithromycin, roxithromycin, dirithromycin, HMR 3004 and azithromycin ( Fig.  1) , exhibit anti-in£ammatory activity. Bronchial hyperresponsiveness in adult asthmatics, endothelin-1, neutrophil oxidant burst, neutrophil chemotaxis and cytokine production [18] , IL-8 release [27] and phagocytes, reactive oxygen species and cytokine levels [12] have been reported to be a¡ected by these macrolide antibiotics. As noted above, macrolides containing a 16-member ring, such as spiramycin and josamycin (Fig. 1) , have been reported as having either no or potent anti-in£ammatory e¡ects. Similarly, the immunosuppressant FK506 (tacrolimus, 23-member ring), which blocks T cell signal transduction by inhibiting calcineurin [28] , has been purported to have variable anti-in£ammatory activity [18] . Some studies have found a potent anti-in£ammatory e¡ect of FK506, particularly in attenuating in£ammatory cell responses to LPS [29^33]. A similar macrolide immunosuppressant, rapamycin, which has a 29-member ring and blocks signal transduction of TOR kinases [34] , appears to be bene¢cial in the control of in£ammation associated with chronic asthma [35, 36] . Neither FK506 nor rapamycin is a true antibacterial macrolide and, as such, detailed comments are beyond the scope of this brief review.
Variation of anti-in£ammatory activity is also seen within the class of 14-member ring macrolides. Using a rat carrageenin paw edema model, Scaglione and Rossoni [17] demonstrated that roxithromycin at a therapeutic dose suppressed carrageenin-induced edema with results almost equal to that seen with non-steroidal anti-in£am-matory drugs. In contrast, azithromycin and clarithromycin exhibited only slight anti-in£ammatory e¡ects in this model. Ianaro et al. [13] examined the e¡ects of four macrolide antibiotics on acute in£ammation using a rat carra- geenin pleurisy model. TNF-K, nitrite plus nitrate (oxidation products of nitric oxide), prostaglandin E 2 , IL-1L, IL-6 and 6-keto-prostaglandin F 1K levels were reduced by macrolide treatment. Reduction in prostanoid and NO x levels could not be attributed to inhibition of inducible nitric oxide synthase (iNOS) or cyclooxygenase-2 since macrolides did not inhibit either enzyme. Speci¢cally, roxithromycin appeared to be more e¡ective than erythromycin and clarithromycin at promoting these inhibitory effects. Azithromycin appeared to only slightly a¡ect the in£ammatory response.
The anti-in£ammatory activities of these macrolide antibiotics appear to depend to a signi¢cant extent on the nature of the sugar moieties that are attached to the macrocyclic ring system. Abdelgha¡ar et al. [37] demonstrated that erythromycin A derivatives that are characterized by the sugar L-cladinose at position 3 of the macrocyclic lactone ring possess anti-in£ammatory properties. These Lcladinose-containing macrolides include erythromycin A, clarithromycin, roxithromycin, dirithromycin and azithromycin [37] (Fig. 1) . The importance of the L-cladinose moiety in modulation of in£ammation is clear although its precise mode of action is still under investigation.
Production of bio¢lms by pathogenic Pseudomonads renders these infections di¤cult to treat with a regimen of antibiotics [38] . Kobayashi [38] investigated the inhibition of P. aeruginosa alginate bio¢lm synthesis by a variety of macrolides. Guanosine diphospho-mannose dehydrogenase (GPMH), a key enzyme in alginate biosynthesis, was found to be inhibited by 14-or 15-membered ring macrolides such as erythromycin, clarithromycin, roxithromycin and azithromycin but not by the 16-membered ring macrolide midecamycin. When the arrangement of the sugar moieties at position 5 of the macrocyclic ring were examined it was found that the 14-and 15-membered rings contained a monosaccharide, desosaminose, while the 16-membered ring of midecamycin contained a disaccharide of mycaminose and mycarose. Removal of the terminal sugar, mycarose, from midecamycin produced an inhibitor of GPMH.
Cellular targets of macrolide antibiotics
A variety of cells found in lungs such as macrophages, polymorphonuclear leukocytes and bronchial epithelial cells have been examined as possible cellular targets for macrolide anti-in£ammatory action in airway disease. A wide variety of physiological mechanisms and biochemical components have also been studied to determine the molecular mechanisms by which macrolide antibiotics exert their anti-in£ammatory e¡ects.
Endogenous production of nitric oxide (NO) by iNOS may be involved in the regulation of normal airway function but may exert deleterious e¡ects when it is inappropriately generated or overproduced [14] . Tamaoki et al. [39] examined the protective e¡ect of macrolides on immune complex-induced lung injury and NO production by rat macrophages. Treatment of macrophages with erythromycin A decreased production of both NO and iNOS mRNA. Immune complex-induced release of the cytokines IL-1L and TNF-K was inhibited by erythromycin A treatment. Erythromycin A treatment was also found to decrease the lung wet-to-dry ratio, suggesting that £uid in¢ltration was decreased. These ¢ndings may suggest that macrolides' inhibition of immune complexmediated NO production may be derived from inhibition of cytokine production [39] . This bene¢cial e¡ect is not con¢ned to erythromycin A alone. Treatment with a variety of other macrolides such as clarithromycin and josamycin has been reported to reduce iNOS-catalyzed NO production and iNOS mRNA transcription [14] .
Macrolides have been implicated in altering the production of a wide variety of molecules and parameters that in£uence the in£ammatory response. Among those in£u-enced are the cytokines (including IL-1, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, granulocyte-macrophage colony stimulating factor (GM-CSF), interferon-Q, TNF-K), oxidant production, chemotaxis and degranulation of neutrophils [12] . The in£uence of the macrolides on the immune system can result in either an increase or a decrease in a particular function leading to complex and somewhat confusing results [12] .
Macrolide therapy often appears to decrease the transcription of mRNA for a variety of cytokines. Kawasaki et al. [40] examined the e¡ect of the macrolide roxithromycin on cytokine production in epithelial cells. Using Bet-1A human bronchial epithelial cells with or without stimulation by IL-1L, they found roxithromycin inhibited IL-8 release and decreased amounts of IL-8 mRNA. Inhibition of IL-6 and GM-CSF was also seen. Takizawa et al. [41] used BEAS-2B human bronchial epithelial cells to examine the e¡ect of erythromycin A on levels of the proin£ammatory cytokine IL-6. In this study, erythromycin A exhibited a dose-dependent suppressive e¡ect on IL-6 release. Northern blot analysis revealed that erythromycin A treatment produced a decrease in the amount of IL-6 mRNA in a dose-dependent manner. Sato et al. [42] examined the e¡ect of erythromycin on eosinophil chemotactic cytokines produced by human lung ¢broblasts. Treatment of these cells in vitro with either IL-1L or TNF-K attenuated the release of eosinophil attractants eotaxin, GM-CSF and RANTES. The e¡ect was most pronounced with eotaxin and erythromycin treatment also signi¢cantly suppressed eotaxin mRNA.
However, post-translational control of cytokine activity may also be in£uenced by macrolides. Long-term e¡ects of erythromycin A on production of some cytokines and chemokines have been examined in rat alveolar macrophages by Sugiyama et al. [43] . TNF-K, cytokine-induced neutrophil chemoattractant-1 (CINC-1, the rat counterpart of human IL-8) and CINC-2 (the rat counterpart of human macrophage in£ammatory peptide-2) were examined after LPS treatment in the presence or absence of erythromycin A. Production of all three cytokines was found to be signi¢cantly lower in macrophages obtained from animals that received low-dose, long-term erythromycin A treatment compared to untreated controls. mRNA levels for these cytokines were not decreased during erythromycin A treatment but were slightly increased, suggesting a possible translational mode of action.
Adhesion of neutrophils to the surface of epithelial cells is an important step in the in£ammatory process and expression of the surface proteins responsible for this phenomenon has been found to be in£uenced by treatment with various macrolides. Lin et al. [44] examined the e¡ect of erythromycin A treatment on L 2 -integrins (CD11b/ CD18) (cell surface adhesion molecules) by LPS-treated neutrophils. Flow cytometric analysis revealed that expression of these cell surface adhesion molecules was decreased following erythromycin A treatment. Interestingly, this decrease was observed in the presence or absence of LPS stimulation of the neutrophils. Kawasaki et al. [40] also examined the e¡ect of the roxithromycin on neutrophil attachment to Bet-1A human bronchial epithelial cells. They found roxithromycin inhibited neutrophil adhesion to Bet-1A bronchial epithelial cells and decreased expression of intracellular adhesion molecule-1 (ICAM-1), with or without stimulation by IL-1L. Macrolide treatment decreased the number of neutrophils in bronchoalveolar lavage £uids from patients with airway in£ammation. Decreased expression of ICAM-1 may explain, in part, the attenuating e¡ects of macrolides on local neutrophil recruitment.
Polymorphonuclear neutrophils (PMN) are an initial defense against pathogens. Their function depends on degradative enzyme release (degranulation), phagocytosis and the production of various oxidant molecules [45] . However, an exaggerated response by PMNs can lead to an increased in£ammatory response and host tissue injury [45] . Initial work showed that degranulation of PMNs is variably a¡ected by macrolides [37] . Dirithromycin was found to induce release of the enzymes lysozyme, lactoferrin and L-galactosidase to a greater extent than either erythromycin or erythromycylamine. Schultz et al. [46] also demonstrated that erythromycin A causes a decrease in the production of CXC chemokines, such as IL-8 and epithelial cell-derived neutrophil attractant 78, while increasing the degranulation of PMN azurophilic and speci¢c granules in whole blood. Extending this work Abdelgha¡ar et al. [45] determined that the presence of the Lcladinose moiety at position 3 of erythromycin A derivatives was required to inhibit PMN oxidant production and for the induction of PMN degranulation while removal of the L-cladinose moiety did not a¡ect PMN degranulation. L-Cladinose-containing erythromycin A derivatives such as roxithromycin have been reported to inhibit the phospholipase D (PLD)^phosphatidate phosphohydrolase (PPH) signal transduction pathway in PMN [45] . This pathway operates in PMN upon activation by particulate or soluble stimuli. Roxithromycin was found to stimulate the PLD activity portion of this pathway leading to an accumulation of the PLD product phosphatidic acid (PA). In contrast, the product of the PPH reaction, diacylglycerol, never increased relative to controls. PA appears to be a key messenger in PMN degranulation [47] and the increase in PA that is seen with roxithromycin treatment correlates well with increased PMN degranulation [45] .
Macrolides target a wide variety of molecules and responses that control the in£ammatory response. Several of these have been brie£y discussed in this review. It will be of great interest to follow research in this area and to discover the details of how all of these intricate processes will be in£uenced by macrolide compounds.
Regulation of cytokine transcription
The decrease in cytokine mRNA transcription, which has been repeatedly demonstrated, as brie£y discussed in the previous section, has led to examination of the mechanisms of this transcriptional control.
Aoki and Kao [48] were the ¢rst to demonstrate that erythromycin A downregulates IL-8 cytokine gene expression in Jurkat T cells by inhibiting transcriptional activation of nuclear factor-UB (NF-UB) through interference with non-calcineurin-dependent signaling pathways. In this respect the inhibitory e¡ect of antibacterial macrolides on transcription of cytokine genes resembles the action of the immunosuppressant rapamycin [34] rather than that of the calcineurin-inhibiting immunosuppressant FK506 [28] . Expanding on the work of Aoki and Kao [48] , Ichiyama et al. [49] used Western blots to demonstrate that clarithromycin suppresses production of proin£ammatory cytokines via inhibition of NF-UB activation and that this inhibition occurs without being linked to preservation of the IUBK regulatory protein. Clarithromycin was found to modulate TNF-K-induced NF-UB activation in T cells, monocytes/macrophages and pulmonary epithelial cells although the precise mechanism of this inhibition remains to be elucidated [49] .
In contrast, Abe et al. [50] examined the role of activa- 
Conclusions
The role of various macrolide antibiotics in the treatment of pulmonary in£ammation appears to be well established. Recent research involving the use of erythromycin and its derivative macrolide antibiotics has shown great promise in treating in£ammation associated with a variety of airway diseases. A wide range of anatomical, physiological, immunological, molecular biological and biochemical processes are known to be a¡ected by these macrolide treatments. The expression and function of cell surface adhesion factors, prostanoids, NO, oxidants such as hydrogen peroxide, many cytokines and other regulatory proteins are bene¢cially a¡ected. Mechanisms for transcriptional regulation and regulation of signal transduction networks that are responsible for modulation of pulmonary in£ammation are being examined. Further exploration of these areas will greatly aid the understanding of the mode of action of these macrolides in decreasing in£ammation in many pulmonary diseases Current research has given much valuable information about the macrolide anti-in£ammatory mode of action but in many cases the precise, exact, complex molecular and biochemical mechanisms have yet to be deciphered in this fascinating and extremely important area of health care research.
